{"id":484058,"date":"2021-04-29T07:05:58","date_gmt":"2021-04-29T11:05:58","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/oncolytics-biotech-announces-upcoming-presentation-at-the-american-society-of-clinical-oncology-annual-meeting\/"},"modified":"2021-04-29T07:05:58","modified_gmt":"2021-04-29T11:05:58","slug":"oncolytics-biotech-announces-upcoming-presentation-at-the-american-society-of-clinical-oncology-annual-meeting","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/oncolytics-biotech-announces-upcoming-presentation-at-the-american-society-of-clinical-oncology-annual-meeting\/","title":{"rendered":"Oncolytics Biotech\u00ae Announces Upcoming Presentation at the American Society of Clinical Oncology Annual Meeting"},"content":{"rendered":"<div class=\"xn-newslines\">\n<p class=\"xn-distributor\">PR Newswire<\/p>\n<\/p><\/div>\n<div class=\"xn-content\">\n<p>\n        <span class=\"xn-location\">SAN DIEGO<\/span> and <span class=\"xn-location\">CALGARY, AB<\/span>, <span class=\"xn-chron\">April 29, 2021<\/span> \/PRNewswire\/ &#8212; Oncolytics Biotech<sup>\u00ae<\/sup>\u00a0Inc. (NASDAQ: ONCY) (TSX: ONC) today announced the acceptance of an abstract discussing its pancreatic adenocarcinoma trial at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, which is taking place virtually from <span class=\"xn-chron\">June 4<\/span> \u2013 8, 2021. Details on the abstract and a corresponding poster presentation are shown below. <\/p>\n<div id=\"prni_dvprnejpg0bb2left\" dir=\"ltr\">\n        <img decoding=\"async\" id=\"prnejpg0bb2left\" title=\"Oncolytics Biotech Logo\" border=\"0\" alt=\"Oncolytics Biotech Logo\" align=\"middle\" src=\"https:\/\/mma.prnewswire.com\/media\/1064079\/Oncolytics_Logo.jpg\" \/>\n      <\/div>\n<p>\n        <b>Title: <\/b>Treatment with pembrolizumab in combination with the oncolytic virus pelareorep promotes anti-tumor immunity in patients with advanced pancreatic adenocarcinoma<br \/><b>Presentation Type: <\/b>Electronic poster<br \/><b>Session Title: <\/b>Gastrointestinal Cancer &#8211; Gastroesophageal, Pancreatic, and Hepatobiliary<br \/>A<b>bstract Number: <\/b>4144<\/p>\n<p>The abstract will be published on the ASCO Annual Meeting website at <span class=\"xn-chron\">5:00 p.m. ET<\/span> on <span class=\"xn-chron\">May 19, 2021<\/span>. The corresponding poster will be made available on the meeting website at <span class=\"xn-chron\">9:00 a.m. ET<\/span> on <span class=\"xn-chron\">June 4, 2021<\/span>.<\/p>\n<p>\n        <b>About Oncolytics Biotech Inc.<br \/><\/b>Oncolytics is a biotechnology company developing pelareorep, an intravenously delivered immuno-oncolytic virus. The compound induces selective tumor lysis and promotes an inflamed tumor phenotype &#8212; turning &#8220;cold&#8221; tumors &#8220;hot&#8221; &#8212; through innate and adaptive immune responses to treat a variety of cancers.<\/p>\n<p>Pelareorep has demonstrated synergies with immune checkpoint inhibitors and may also be synergistic with other approved immuno-oncology agents. Oncolytics is currently conducting and planning additional studies of pelareorep in combination with checkpoint inhibitors and targeted therapies in solid and hematological malignancies, as it prepares for a phase 3 registration study in metastatic breast cancer. For further information, please visit:\u00a0<a target=\"_blank\" href=\"http:\/\/www.oncolyticsbiotech.com\/\" rel=\"nofollow noopener\">www.oncolyticsbiotech.com<\/a>.<\/p>\n<p>\n        <i>This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended and forward-looking information under applicable Canadian securities laws (such forward-looking statements and forward-looking information are collectively referred to herein as &#8220;forward-looking statements&#8221;). Forward-looking statements contained in this press release include statements regarding Oncolytics&#8217; belief as to the potential and benefits of pelareorep as a cancer therapeutic; Oncolytics&#8217; expectations as to the purpose, design, outcomes and benefits of its current or pending clinical trials involving pelareorep; and other statements related to anticipated developments in Oncolytics&#8217; business and technologies.\u00a0 In any forward-looking statement in which Oncolytics expresses an expectation or belief as to future results, such expectations or beliefs are expressed in good faith and are believed to have a reasonable basis, but there can be no assurance that the statement or expectation or belief will be achieved. Such forward-looking statements involve known and unknown risks and uncertainties, which could cause Oncolytics&#8217; actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue research and development projects, the efficacy of pelareorep as a cancer treatment, the success and timely completion of clinical studies and trials, Oncolytics&#8217; ability to successfully commercialize pelareorep, uncertainties related to the research and development of pharmaceuticals, uncertainties related to the regulatory process and general changes to the economic environment. In particular, we may be impacted by business interruptions resulting from COVID-19 coronavirus, including operating, manufacturing supply chain, clinical trial and project development delays and disruptions, labour shortages, travel and shipping disruption, and shutdowns (including as a result of government regulation and prevention measures). It is unknown whether and how Oncolytics may be affected if the COVID-19 pandemic persists for an extended period of time. We may incur expenses or delays relating to such events outside of our control, which could have a material adverse impact on our business, operating results and financial condition.\u00a0 Investors should consult Oncolytics&#8217; quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned against placing undue reliance on forward-looking statements. The Company does not undertake any obligation to update these forward-looking statements, except as required by applicable laws.<\/i>\n      <\/p>\n<div class=\"prntal\">\n<table cellspacing=\"0\" cellpadding=\"0\" border=\"0\" class=\"prntblns\">\n<tr>\n<td class=\"prngen2\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>Company Contact <\/b><br \/>\n                <\/span>\n              <\/p>\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">Kirk Look<\/span>\n              <\/p>\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">Chief Financial Officer<\/span>\n              <\/p>\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">+1-403-670-7658 <\/span>\n              <\/p>\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\"><br \/>\n                  <a target=\"_blank\" href=\"mailto:KLook@oncolytics.ca\" class=\"prnews_a\" rel=\"nofollow noopener\">KLook@oncolytics.ca<\/a>\u00a0<\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen2\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>Investor Relations for Oncolytics<\/b><br \/>\n                <\/span>\n              <\/p>\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">Timothy McCarthy<\/span>\n              <\/p>\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">LifeSci Advisors<\/span>\n              <\/p>\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">+1-917-679-9282<\/span>\n              <\/p>\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\"><br \/>\n                  <a target=\"_blank\" href=\"mailto:tim@lifesciadvisors.com\" class=\"prnews_a\" rel=\"nofollow noopener\">tim@lifesciadvisors.com<\/a><br \/>\n                <\/span>\n              <\/p>\n<\/td>\n<\/tr>\n<\/table><\/div>\n<p>Logo: <a target=\"_blank\" href=\"https:\/\/mma.prnewswire.com\/media\/1064079\/Oncolytics_Logo.jpg\" rel=\"nofollow noopener\">https:\/\/mma.prnewswire.com\/media\/1064079\/Oncolytics_Logo.jpg<\/a><br \/>\u00a0 <\/p>\n<p \/>\n<p id=\"PURL\">\n        <img loading=\"lazy\" decoding=\"async\" title=\"Cision\" width=\"12\" height=\"12\" alt=\"Cision\" src=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=LN59774&amp;sd=2021-04-29\" \/> View original content:<a id=\"PRNURL\" rel=\"nofollow\" href=\"http:\/\/www.prnewswire.com\/news-releases\/oncolytics-biotech-announces-upcoming-presentation-at-the-american-society-of-clinical-oncology-annual-meeting-301279677.html\">http:\/\/www.prnewswire.com\/news-releases\/oncolytics-biotech-announces-upcoming-presentation-at-the-american-society-of-clinical-oncology-annual-meeting-301279677.html<\/a><\/p>\n<p>SOURCE  Oncolytics Biotech\u00ae Inc.<\/p>\n<\/p><\/div>\n<p>    <img decoding=\"async\" alt=\"\" src=\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=LN59774&amp;Transmission_Id=202104290700PR_NEWS_USPR_____LN59774&amp;DateId=20210429\" style=\"border:0px;width:1px;height:1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>PR Newswire SAN DIEGO and CALGARY, AB, April 29, 2021 \/PRNewswire\/ &#8212; Oncolytics Biotech\u00ae\u00a0Inc. (NASDAQ: ONCY) (TSX: ONC) today announced the acceptance of an abstract discussing its pancreatic adenocarcinoma trial at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, which is taking place virtually from June 4 \u2013 8, 2021. Details on the abstract and a corresponding poster presentation are shown below. Title: Treatment with pembrolizumab in combination with the oncolytic virus pelareorep promotes anti-tumor immunity in patients with advanced pancreatic adenocarcinomaPresentation Type: Electronic posterSession Title: Gastrointestinal Cancer &#8211; Gastroesophageal, Pancreatic, and HepatobiliaryAbstract Number: 4144 The abstract will be published on the ASCO Annual Meeting website at 5:00 p.m. ET on May 19, 2021. The corresponding poster will &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/oncolytics-biotech-announces-upcoming-presentation-at-the-american-society-of-clinical-oncology-annual-meeting\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Oncolytics Biotech\u00ae Announces Upcoming Presentation at the American Society of Clinical Oncology Annual Meeting&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-484058","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Oncolytics Biotech\u00ae Announces Upcoming Presentation at the American Society of Clinical Oncology Annual Meeting - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/oncolytics-biotech-announces-upcoming-presentation-at-the-american-society-of-clinical-oncology-annual-meeting\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Oncolytics Biotech\u00ae Announces Upcoming Presentation at the American Society of Clinical Oncology Annual Meeting - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire SAN DIEGO and CALGARY, AB, April 29, 2021 \/PRNewswire\/ &#8212; Oncolytics Biotech\u00ae\u00a0Inc. (NASDAQ: ONCY) (TSX: ONC) today announced the acceptance of an abstract discussing its pancreatic adenocarcinoma trial at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, which is taking place virtually from June 4 \u2013 8, 2021. Details on the abstract and a corresponding poster presentation are shown below. Title: Treatment with pembrolizumab in combination with the oncolytic virus pelareorep promotes anti-tumor immunity in patients with advanced pancreatic adenocarcinomaPresentation Type: Electronic posterSession Title: Gastrointestinal Cancer &#8211; Gastroesophageal, Pancreatic, and HepatobiliaryAbstract Number: 4144 The abstract will be published on the ASCO Annual Meeting website at 5:00 p.m. ET on May 19, 2021. The corresponding poster will &hellip; Continue reading &quot;Oncolytics Biotech\u00ae Announces Upcoming Presentation at the American Society of Clinical Oncology Annual Meeting&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/oncolytics-biotech-announces-upcoming-presentation-at-the-american-society-of-clinical-oncology-annual-meeting\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-04-29T11:05:58+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/1064079\/Oncolytics_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncolytics-biotech-announces-upcoming-presentation-at-the-american-society-of-clinical-oncology-annual-meeting\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncolytics-biotech-announces-upcoming-presentation-at-the-american-society-of-clinical-oncology-annual-meeting\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Oncolytics Biotech\u00ae Announces Upcoming Presentation at the American Society of Clinical Oncology Annual Meeting\",\"datePublished\":\"2021-04-29T11:05:58+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncolytics-biotech-announces-upcoming-presentation-at-the-american-society-of-clinical-oncology-annual-meeting\\\/\"},\"wordCount\":683,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncolytics-biotech-announces-upcoming-presentation-at-the-american-society-of-clinical-oncology-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1064079\\\/Oncolytics_Logo.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncolytics-biotech-announces-upcoming-presentation-at-the-american-society-of-clinical-oncology-annual-meeting\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncolytics-biotech-announces-upcoming-presentation-at-the-american-society-of-clinical-oncology-annual-meeting\\\/\",\"name\":\"Oncolytics Biotech\u00ae Announces Upcoming Presentation at the American Society of Clinical Oncology Annual Meeting - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncolytics-biotech-announces-upcoming-presentation-at-the-american-society-of-clinical-oncology-annual-meeting\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncolytics-biotech-announces-upcoming-presentation-at-the-american-society-of-clinical-oncology-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1064079\\\/Oncolytics_Logo.jpg\",\"datePublished\":\"2021-04-29T11:05:58+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncolytics-biotech-announces-upcoming-presentation-at-the-american-society-of-clinical-oncology-annual-meeting\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncolytics-biotech-announces-upcoming-presentation-at-the-american-society-of-clinical-oncology-annual-meeting\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncolytics-biotech-announces-upcoming-presentation-at-the-american-society-of-clinical-oncology-annual-meeting\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1064079\\\/Oncolytics_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1064079\\\/Oncolytics_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncolytics-biotech-announces-upcoming-presentation-at-the-american-society-of-clinical-oncology-annual-meeting\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Oncolytics Biotech\u00ae Announces Upcoming Presentation at the American Society of Clinical Oncology Annual Meeting\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Oncolytics Biotech\u00ae Announces Upcoming Presentation at the American Society of Clinical Oncology Annual Meeting - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/oncolytics-biotech-announces-upcoming-presentation-at-the-american-society-of-clinical-oncology-annual-meeting\/","og_locale":"en_US","og_type":"article","og_title":"Oncolytics Biotech\u00ae Announces Upcoming Presentation at the American Society of Clinical Oncology Annual Meeting - Market Newsdesk","og_description":"PR Newswire SAN DIEGO and CALGARY, AB, April 29, 2021 \/PRNewswire\/ &#8212; Oncolytics Biotech\u00ae\u00a0Inc. (NASDAQ: ONCY) (TSX: ONC) today announced the acceptance of an abstract discussing its pancreatic adenocarcinoma trial at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, which is taking place virtually from June 4 \u2013 8, 2021. Details on the abstract and a corresponding poster presentation are shown below. Title: Treatment with pembrolizumab in combination with the oncolytic virus pelareorep promotes anti-tumor immunity in patients with advanced pancreatic adenocarcinomaPresentation Type: Electronic posterSession Title: Gastrointestinal Cancer &#8211; Gastroesophageal, Pancreatic, and HepatobiliaryAbstract Number: 4144 The abstract will be published on the ASCO Annual Meeting website at 5:00 p.m. ET on May 19, 2021. The corresponding poster will &hellip; Continue reading \"Oncolytics Biotech\u00ae Announces Upcoming Presentation at the American Society of Clinical Oncology Annual Meeting\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/oncolytics-biotech-announces-upcoming-presentation-at-the-american-society-of-clinical-oncology-annual-meeting\/","og_site_name":"Market Newsdesk","article_published_time":"2021-04-29T11:05:58+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/1064079\/Oncolytics_Logo.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncolytics-biotech-announces-upcoming-presentation-at-the-american-society-of-clinical-oncology-annual-meeting\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncolytics-biotech-announces-upcoming-presentation-at-the-american-society-of-clinical-oncology-annual-meeting\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Oncolytics Biotech\u00ae Announces Upcoming Presentation at the American Society of Clinical Oncology Annual Meeting","datePublished":"2021-04-29T11:05:58+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncolytics-biotech-announces-upcoming-presentation-at-the-american-society-of-clinical-oncology-annual-meeting\/"},"wordCount":683,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncolytics-biotech-announces-upcoming-presentation-at-the-american-society-of-clinical-oncology-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/1064079\/Oncolytics_Logo.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncolytics-biotech-announces-upcoming-presentation-at-the-american-society-of-clinical-oncology-annual-meeting\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/oncolytics-biotech-announces-upcoming-presentation-at-the-american-society-of-clinical-oncology-annual-meeting\/","name":"Oncolytics Biotech\u00ae Announces Upcoming Presentation at the American Society of Clinical Oncology Annual Meeting - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncolytics-biotech-announces-upcoming-presentation-at-the-american-society-of-clinical-oncology-annual-meeting\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncolytics-biotech-announces-upcoming-presentation-at-the-american-society-of-clinical-oncology-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/1064079\/Oncolytics_Logo.jpg","datePublished":"2021-04-29T11:05:58+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncolytics-biotech-announces-upcoming-presentation-at-the-american-society-of-clinical-oncology-annual-meeting\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/oncolytics-biotech-announces-upcoming-presentation-at-the-american-society-of-clinical-oncology-annual-meeting\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncolytics-biotech-announces-upcoming-presentation-at-the-american-society-of-clinical-oncology-annual-meeting\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/1064079\/Oncolytics_Logo.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/1064079\/Oncolytics_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncolytics-biotech-announces-upcoming-presentation-at-the-american-society-of-clinical-oncology-annual-meeting\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Oncolytics Biotech\u00ae Announces Upcoming Presentation at the American Society of Clinical Oncology Annual Meeting"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/484058","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=484058"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/484058\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=484058"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=484058"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=484058"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}